Literature DB >> 1735988

Applicability of noncardioplegic coronary bypass to high-risk patients. Selection of patients, technique, and clinical experience in 3000 patients.

L I Bonchek1, M W Burlingame, B E Vazales, E F Lundy, C J Gassmann.   

Abstract

Although some surgeons still prefer noncardioplegic coronary bypass, most surgeons are skeptical of its suitability for high-risk patients. We analyzed the first 3000 patients who had primary coronary bypass without cardioplegia since our program's inception. Patients with reoperations, valve operations, or carotid endarterectomies were excluded. Multivariate predictors of operative death included age, sex, left ventricular dysfunction, preoperative intraaortic balloon pumping, and urgency of operation. Eight hundred seventy-nine patients (29%) were more than 70 years of age; 795 (27%) were female; 290 (9.7%) had an ejection fraction less than 0.30, and another 77 (2.6%) had left ventricular aneurysms; 196 (6.5%) had an acute myocardial infarction, and another 397 (13%) had a myocardial infarction less than 1 week preoperatively; 917 (31%) had rest pain in the hospital (preinfarction angina). Only 790 (26%) had elective operations. The overall operative mortality rate was 1.47% (44/3000): The mortality rate for elective operations was 0.5% (4/790); urgent 1.7% (28/1687); emergency 2.3% (12/523). In patients with an ejection fraction less than 0.30 the mortality rate was 6.2% (18/290); with age more than 70 years, it was 3.9% (34 of 879); with acute myocardial infarction it was 3.1% (6/196); and with left ventricular aneurysmectomy it was 1.3% (1/77). Inotropic support after leaving the operating room was needed in 6.6% (199 patients), and 1% (30 patients) required new intraaortic balloon pumping postoperatively (two of these 30 patients died). These results provide reassurance that noncardioplegic coronary artery bypass grafting provides excellent myocardial protection and operating conditions for primary coronary bypass and is particularly suitable for high-risk patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735988

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  Protecting the damaged heart during coronary surgery.

Authors:  D J Wheatley
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

2.  Intermittent ischaemic arrest and cardioplegia in coronary artery surgery: coming full circle?

Authors:  D P Taggart; S Bhusari; J Hopper; M Kemp; P Magee; J E Wright; R Walesby
Journal:  Br Heart J       Date:  1994-08

3.  Coronary surgery with non-cardioplegic methods in patients with advanced left ventricular dysfunction: immediate and long term results.

Authors:  P E Antunes; J M Ferrão de Oliveira; M J Antunes
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

4.  Lack of cardioprotective efficacy of allopurinol in coronary artery surgery.

Authors:  D P Taggart; V Young; J Hooper; M Kemp; R Walesby; P Magee; J E Wright
Journal:  Br Heart J       Date:  1994-02

5.  Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study.

Authors:  Joel Dunning; Steven Hunter; Simon W H Kendall; John Wallis; W Andrew Owens
Journal:  J Cardiothorac Surg       Date:  2006-11-21       Impact factor: 1.637

6.  Improvement in cardioplegic perfusion technique in single aortic clamping - initial results.

Authors:  Marcelo Luiz Peixoto Sobral; Sérgio Francisco dos Santos Júnior; Juliano Cavalcante de Sá; Anderson da Silva Terrazas; Daniel Francisco de Mendonça Trompieri; Thierry Araújo Nunes de Sousa; Gilmar Geraldo dos Santos; Noedir Antonio Groppo Stolf
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Apr-Jun

7.  Modifiable risk factors remain significant causes of medium term mortality after first time Coronary artery bypass grafting.

Authors:  Babu Kunadian; Joel Dunning; Russell W J Millner
Journal:  J Cardiothorac Surg       Date:  2007-12-03       Impact factor: 1.637

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.